# IGC Pharma, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/IGC Pharma, Inc.). ## Overview IGC Pharma, Inc. is a U.S.-based clinical-stage pharmaceutical company focused on Alzheimer’s disease and related neurodegenerative conditions. Its lead program, IGC-AD1, is in Phase 2 testing for agitation in Alzheimer’s dementia, while the company also sells a small portfolio of white-label, private-label, and branded wellness products through its Life Sciences segment. ## Products & services • IGC-AD1 Phase 2 Alzheimer’s agitation candidate • TGR-63 pre-clinical Alzheimer’s candidate • MINT-AD early-diagnosis Alzheimer’s program • White-label manufactured formulations • Private-label and branded wellness products • Contract research / internal trial operations - **Clinical-stage therapeutics** (0%) — Investigational Alzheimer’s and neurodegenerative disease drug candidates in preclinical and Phase 2 development. - **Life Sciences consumer and white-label products** (100%) — Manufactured formulations, white-label products, and branded wellness items sold commercially. - **Research and development services** (0%) — Internal clinical development, trial operations, and related scientific work supporting pipeline advancement. - IGC-AD1 Phase 2 candidate for agitation in Alzheimer’s disease - TGR-63 pre-clinical candidate with potential disease-modifying effects - MINT-AD early-diagnosis program for Alzheimer’s disease - White-label manufactured formulations sold through Life Sciences - Private-label and branded wellness / holistic health products - Internal CRO-style clinical trial and regulatory execution ## Customers IGC Pharma sells primarily to commercial buyers of manufactured wellness and formulation products, while its core therapeutic pipeline is aimed at patients with Alzheimer’s disease and the caregivers and clinicians who influence treatment adoption. The company’s near-term revenue base is small and concentrated, with two customers each accounting for more than 10% of sales in fiscal 2025. Its longer-term value proposition is directed at physicians, patients, and healthcare systems seeking better options for agitation and other Alzheimer’s-related symptoms. - **Commercial formulation customers** (primary) — Buy white-label and private-label manufactured products for resale or distribution. - **Branded wellness consumers** (secondary) — Purchase holistic health and branded products through retail and online channels. - **Alzheimer’s patients and caregivers** (primary) — The end market for IGC-AD1 and future neurodegenerative therapies aimed at symptom relief. - **Healthcare partners and licensees** (emerging) — Potential collaborators that may help fund, develop, or commercialize pipeline assets. - White-label and private-label buyers of manufactured formulations - Retail and online wellness customers for branded products - Patients with Alzheimer’s disease targeted by IGC-AD1 - Caregivers and clinicians seeking agitation treatments - Potential licensing and partnership counterparties ## Geography IGC Pharma is headquartered in the United States and manufactures products in Vancouver, Washington, which is important to its Life Sciences supply chain. The company’s reported revenue disclosures do not provide a country-by-country sales split, but its operations are clearly U.S.-centric and exposed to U.S. FDA and state-level regulatory requirements. The disposition of the Vancouver facility also affected production and fulfillment during fiscal 2025, reducing near-term commercial output. - Headquartered in the United States - Manufacturing and fulfillment tied to Vancouver, Washington - U.S. FDA oversight is central to pipeline commercialization - No country-level revenue split was disclosed in the excerpts - Facility disposition temporarily reduced production and shipments ## Strategy IGC Pharma is prioritizing advancement of IGC-AD1 through Phase 2 clinical development while building a broader Alzheimer’s pipeline, including TGR-63 and MINT-AD. Management is also trying to preserve commercial optionality by keeping a small Life Sciences product business, using internal trial operations to control costs, and seeking external capital and non-dilutive funding to support R&D. - **Complete Phase 2 development of IGC-AD1** (short-term) — The lead asset is the main driver of future value and clinical validation. - **Expand the Alzheimer’s pipeline** (medium-term) — A broader pipeline reduces single-asset dependence and improves partnering potential. - **Preserve liquidity and access to capital** (short-term) — The company remains loss-making and needs funding to sustain R&D and trials. - **Use internal execution to lower trial costs** (medium-term) — Lower per-patient trial costs improve capital efficiency and extend runway. - Advance IGC-AD1 through Phase 2 and toward later-stage development - Build a broader Alzheimer’s pipeline beyond the lead candidate - Develop AI-enabled tools for early Alzheimer’s detection - Use internal trial operations to control clinical development costs - Maintain a small commercial product base while focusing on pharma - Raise capital through equity, ATM, private placement, and grants ## Risks IGC Pharma faces the typical risks of a clinical-stage biotech company: trial failure, regulatory delay, and the possibility that its lead asset never reaches commercialization. It also has a very small revenue base, concentrated customers and suppliers, and ongoing dependence on equity financing, which can dilute shareholders and increase volatility. The company’s newer digital-asset treasury policy adds mark-to-market and regulatory risk on top of its existing operating and funding risks. - **Lead program may fail in clinical development** [high] — IGC-AD1 is still in Phase 2, so efficacy or safety issues could stop commercialization. - **Dependence on external financing** [high] — The company has recurring losses and limited cash, so it relies on equity raises and other funding. - **Customer and supplier concentration** [medium] — A few customers and suppliers account for a meaningful share of activity, increasing disruption risk. - **Digital asset treasury volatility** [medium] — Mark-to-market changes on ETP holdings can affect reported earnings and liquidity perception. - **Competitive pressure in Alzheimer’s therapeutics** [high] — Larger pharmaceutical companies have more capital, development capacity, and commercialization reach. - Clinical trial failure or weak data could impair IGC-AD1 value - FDA approval risk remains high for all investigational programs - Revenue is small and customer concentration is elevated - Ongoing equity financing may dilute existing shareholders - Digital asset investments can add volatility to earnings and liquidity - Competition from better-funded pharma companies is intense ## Accounting Revenue recognition is important because the company earns a mix of product sales and white-label manufacturing revenue, which can fluctuate with product mix and fulfillment timing. Investors should also watch impairment and fair-value accounting, since the company has reported asset impairments and now marks digital-asset ETP holdings to market through earnings. As a loss-making biotech, estimates around inventory, receivables, stock compensation, and long-lived asset recoverability can materially affect reported results. - **Revenue recognition under ASC 606** — Affects quarterly revenue and gross margin comparability - **Digital asset fair-value accounting** — Can introduce non-operating volatility in net loss - **Impairment of long-lived assets** — Can materially reduce operating results in a period - **Stock-based compensation and warrant valuation** — Affects operating expenses and shareholder dilution analysis - Revenue timing depends on product sales and manufacturing fulfillment - Gross margin varies with mix between white-label, private-label, and branded products - Digital asset ETPs are marked to market through earnings - Long-lived asset and PPE impairment can create one-time charges - Stock-based compensation and valuation estimates affect reported losses --- *Last updated: 2026-04-28T20:15:38.398823+00:00*